Safety Study of Lactobacillus Administered Vaginally to Healthy Women

Inclusion Criteria: * Healthy pre-menopausal women 18- 40 years of age at date of screening. * Regular menstrual cycles (21-35 days) or amenorrheic for at least 3 months (long acting progestin contraceptives). * Normal Pap smear collected at the screening visit. * Previous sexual experience including vaginal intercourse. * Previous experience of gynecological examinations. * Currently in a mutually monogamous sexual relationship or not sexually active. * Agree to be sexually abstinent thoughout the trial. * Agree to abstain from the use of any other intravaginal product thoughout the trial * Agree to use an adequate method of birth control for the duration of the study to avoid pregnancy. Exclusion Criteria: * Urogenital infection at screening or within the 21 days prior to screening (UTI, bacterial vaginosis, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum or Herpes simplex). * History of recurrent genital herpes. * Diagnosis of N. gonorrhoeae, C. trachomatis, T. pallidum or T. vaginalis on two or more occasions during the six months prior to screening. * Pregnancy or within 2 months of last pregnancy. * Lactation. * Antibiotic or antifungal therapy within 30 days of enrollment visit. * Concurrent investigational drug use within 30 days or 10 half-lives of the drug, of enrollment visit or during the study. * Menopause. * IUD insertion or removal, pelvic surgery, cervical cryotherapy or cervical laser within the last 3 months. * Use of a NuvaRing® within 3 days of the screening visit or during the course of the study. * New (less than 3 months)long-acting treatments (e.g. depot formulation including medroxyprogesterone acetate (DMPA) form of hormonal birth control). - - Diabetes or other significant disease or acute illness. * Known HIV infection or positive HIV test at screening. * Immunosuppressive drug within 60 days. * Previous participation in a L. crispatus CTV-05 clinical study. * Colposcopic findings at the enrollment visit involving significant deep disruption of the epithelium. * Abnormal results for the pap smear at the screening visit. * Known allergy to any component of LACTIN-V, other significant drug allergy or to latex (condoms). * Known drug or alcohol abuse.